By using MHY1485 (10 μM, 1 μL per side) to evaluate the pro-neurogenic effect of COS, and found that MHY1485 abolished the increased number of BrdU+Sox2+GFAP+ RGLs, BrdU+DCX+ neuroblasts, and BrdU+NeuN+ neurons in DG of CRS-exposed mice after COS treatment (Fig. 5a-c), suggesting that mTOR activator abolishes the pro-neurogenic effect of COS treatment. The gene discussed is MTOR; the disease is congenital rubella syndrome.